Overview

AU2 In Relapsed and Untreated CLL

Status:
Recruiting

Trial end date:
2030-01-01

Target enrollment:

Participant gender:

Summary

This study is testing the effectiveness of the study drug combination of acalabrutinib, umbralisib, and ublituximab in participants with Chronic Lymphocytic leukemia (CLL). The names of the study drugs involved in this study are/is: - Acalabrutinib (CALQUENCE®, ACP-196) - Umbralisib (TGR-1202) - Ublituximab (TG-1101)

Phase:

Phase 2

Details

Lead Sponsor:

Jennifer R. Brown, MD, PhD

Collaborators:

AstraZeneca
TG Therapeutics, Inc.

Treatments:

Acalabrutinib